In a report released on March 21, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

Connor Clark & Lunn Investment Management Ltd. lowered its position in Novartis AG (NYSE:NVS – Free Report) by 95.6% in the 4th quarter, according to the company in its most recent Form 13F filing ...

Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Matein Khalid Risk assets went ballistic this week as DonnyT did his tariff man war dance, hurled his Tomahawk at Canada, Mexico, China ...

Morgan Stanley analyst Judah Frommer notes that Novartis (NVS) has received FDA approval for Fabhalta for C3G. The label comes with a few important restrictions/caveats that leave room for Apellis’s ...

Disitamab vedotin, an antibody-drug conjugate (ADC), targets HER2-expressing cancer cells. It works by binding to HER2, being ...

Connor Clark & Lunn Investment Management Ltd. lowered its stake in shares of Elme Communities (NYSE:ELME – Free Report) by 3 ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.